文献速递肝病

综述:失代偿期自身免疫性肝炎肝硬化中的免疫抑制——抑制还是不抑制?

Review article: Immunosuppression in Decompensated Autoimmune Hepatitis Cirrhosis - To Suppress or Not to Suppress?
PubMed 文献 · Aliment Pharmacol Ther · 2026-08-03

本综述综合观察性与回顾性数据,探讨失代偿期自身免疫性肝炎肝硬化是否启用免疫抑制治疗。核心矛盾在于抑制炎症活动与避免感染、治疗无效及延误肝移植之间的权衡。临床再代偿率仅19%-31%,建议对选定患者进行限时免疫抑制试验并设定严格停药规则。

要点

  • 失代偿期AIH肝硬化免疫抑制治疗窗窄,需个体化风险分层决策。
  • 临床再代偿率19%-31%,低于其他病因肝硬化。
  • 第1周和第4周胆红素与MELD-Na动态变化可区分应答者与需紧急肝移植者。

核心结论

  • 管理应从一刀切转向个体化、协议化策略,对选定候选者进行限时免疫抑制试验,并设定严格停药规则。
  • 非应答者或高危患者应立即进行肝移植评估。

研究设计与样本

  • 本综述综合当前观察性数据和回顾性研究,聚焦患者选择、医疗干预的治疗窗及肝硬化相关免疫功能障碍的生理影响。

主要发现

  • 临床再代偿在19%-31%的病例中可实现,但频率低于其他病因。
  • 第1周和第4周胆红素与MELD-Na的早期动态变化有助于区分应答者与需紧急肝移植者。
  • 肝移植提供优异的长期生存,但20%的病例出现复发。

关键数值与推荐

  • 临床再代偿率19%-31%。
  • 肝移植后AIH复发率20%。
  • 早期动态应答评估包括第1周和第4周胆红素与MELD-Na的变化。

临床怎么用

  • 对选定候选者进行限时免疫抑制试验,并设定严格停药规则。
  • 非应答者或高危患者立即进行肝移植评估。
  • 利用第1周和第4周胆红素与MELD-Na动态变化区分应答者与需紧急移植者。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The management of decompensated autoimmune hepatitis (AIH) cirrhosis is one of the most challenging and controversial scenarios in hepatology. Clinicians face a high-stakes dilemma: whether to initiate immunosuppression to halt inflammatory activity or prioritize liver transplantation (LT) referral to avoid treatment futility and life-threatening infections. AIMS: To critically appraise the evidence regarding immunosuppression in decompensated AIH cirrhosis and propose a biologically grounded, risk-stratified framework for clinical decision-making. METHODS: This review synthesizes current observational data and retrospective studies, focusing on patient selection, the 'therapeutic window' for medical intervention and the physiological impact of cirrhosis-associated immune dysfunction. RESULTS: The risks of infection, treatment futility and delayed transplant access must be weighed against the possibility of halting inflammatory activity and achieving clinical stabilization. A narrow therapeutic window exists for medical therapy. Clinical 'recompensation' is achievable in 19%-31% of cases, though this is less frequent than in other etiologies. Early dynamic response assessment-specifically changes in bilirubin and MELD-Na at weeks 1 and 4-helps distinguish responders from those requiring urgent LT. While LT offers excellent long-term survival, recurrence occurs in 20% of cases. CONCLUSIONS: Management must shift from a 'one-size-fits-all' approach to an individualized, protocolized strategy. We advocate for a time-limited trial of immunosuppression in selected candidates, governed by strict 'stop rules' and immediate LT evaluation for non-responders or high-risk patients.

来源:Aliment Pharmacol Ther,查看原文。版权归原作者所有。

引用

  1. Passos PRC, Filho VOC, Cançado GGL, et al. Review article: Immunosuppression in Decompensated Autoimmune Hepatitis Cirrhosis - To Suppress or Not to Suppress? Aliment Pharmacol Ther. 2026. PMID: 42544833. doi:10.1111/apt.70893

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。